Abstract
Innovative gene therapy approaches for brain tumour-related epilepsy Professor Mark Cunningham and Dr Kate Connor from Trinity College Dublin discuss the burden of brain tumour-related epilepsy and why novel therapies are urgently needed to improve the quality of life for those affected. Brain tumour-related epilepsy (BTRE) is a unique and devastating condition which embraces two serious pathologies. BTRE incidence is inversely correlated to malignancy, with seizures as the first presenting symptom in 65-85% of patients with low-grade gliomas (LGG) and 30-60% with glioblastoma (GBM). (1) Seizures often manifest as complications throughout brain tumour evolution. Clinical management via radiotherapy, chemotherapy, and antiepileptic drugs (AEDs) can reduce seizure frequency, but many patients continue to experience seizures following therapeutic intervention. (2) Overall, BTRE is a debilitating and difficult-to-control condition, with seizures closely linked to tumour recurrence and progression.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
